美罗华联合CHOP治疗B细胞性非霍奇金淋巴瘤的临床研究

Clinical study of rituximab combining with CHOP treating B cell non-Hodgkin lymphoma

目的:评价美罗华与CHOP联合治疗B细胞性非霍奇金淋巴瘤的临床效果及不良反应。方法:用同期对照的前瞻性研究方法,将22例B细胞性非霍奇金淋巴瘤患者分为治疗组和对照组,治疗组11例用CHOP方案(环磷酰胺、阿霉素、长春新碱和泼尼)联合美罗华治疗,对照组11例单用CHOP方案。所有病例21 d为1个治疗周期,6个周期后评价。将两组患者按国际淋巴瘤预后因子指数分为中低危组和高危组,分析其疗效与预后。结果:治疗组完全缓解率达72.7%,总有效率90.9%;对照组完全缓解率为36.4%,总有效率为54.5%,两组疗效差异有统计学意义(P<0.001)。结论:美罗华联合CHOP方案治疗CD20+的B细胞性非霍奇金淋巴瘤疗效显著,不良反应与单纯化疗相似,可作为该病目前的首选方案。

Objective To evaluate the therapeutic effects and side-effects of rituximab combining with CHOP on B cell non-Hodgkin lymphoma. Methods A prospective study with concurrent control group was adopted. 22 cases with B cell non-Hodgkin lymphoma were divided into 2 groups. The 11 cases in research group （rituximab group）were administered rituximab combining with CHOP（ cyclophosphamide, doxorubicin, vincristine, and prednisone） regimen. The remaining 11 cases in the control group were treated with CHOP regimen only. All cases were received a course of 21 d and were evaluated after 6 coueses. The two groups were divided into high-risk and low-inter-mediate-risk subgroups according to the international prognosis index（IPI）. Then we analyzed the relationship between the effects and IPI. Results The complete remission（CR） rate and total effective rate in rituximab group were 72.7% and 90.9% respectively,while those corresponding rates in control group were 36.4% and 54.5% respectively. The therapeutic differences between two groups showed statistical significance （ P 〈 0. 001 ）. Conclusion Comparing with CHOP regimen chemotherapy, rituximab combining CHOP regimen showes higher therapeutic effect. The side-effects were concordant in the two groups. Rituximab combining CHOP regimen should be the first choice in treating B cell non-Hodgkin lymphoma.